{"slug":"p21","seoKey":"p21","displayName":"P021 (P21)","codes":["P021","P21"],"synonyms":["P-21","Peptide 021","Peptide 21","P-21 nootropic peptide","Ac-DGGL-Ag-NH2","Ac-DGGLAG-NH2","Ac-DGGL(A)G-NH2","CNTF small-molecule peptide mimetic"],"legalClass":"research_chemical","identifiers":{"cas":"1246751-68-7","pubchemCid":56599151,"unii":"VV8CZC8PAS","inchikey":"LUJZBZPLIRWWGJ-ZKHAZHQOSA-N","formula":"C27H42N6O8","molecularWeight":578.7,"sequence":"Ac-DGGL-Ag-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, in any dosage form and for any indication, and not a component of an approved medicine. Four queries on 2026-09-16: the drug approval records and the labelling endpoint both returned NOT_FOUND for the substance name, and the labelling service of the national library returned zero elements at a database state of 2026-09-15; control queries for an approved medicine returned records on every one of those endpoints. The substance appears on neither compounding list: not among the bulk substances used in compounding under section 503A, and not in the category of bulk substances that may present significant safety risks, nor among its withdrawn nominations. Controls found in the same documents include ibutamoren mesylate, GHRP-2, GHRP-6, ipamorelin acetate, kisspeptin-10, BPC-157, CJC-1295, selank acetate, semax and thymosin alpha-1. That absence is not reassurance: it means there is no lawful route to prepare the substance for a person, and anything dispensed under this name is an unapproved new drug.","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"No authorisation as a medicine, neither centrally nor nationally, no orphan designation and no registered clinical trial. The European trial register was searched on 2026-09-16 and answered, in those words, that the query did not match any clinical trials and did not match any studies, in both parts of the register. The substance was never the subject of a marketing application, so the general authorisation requirement applies in full and placing it on the market is not permitted.","source":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=P021"},{"market":"DE","status":"not_approved","note":"Not an authorised medicine: no centrally authorised product and no national finished medicine, so every preparation is an unapproved medicine and advertising to the public is prohibited. Separately checked and worth stating plainly: the substance is NOT named in the annex to the anti-doping act. The full text of that annex, in its 2023 version, was read on 2026-09-16; section II number 3 on growth factors and growth factor modulators names only mecasermin, IGF-1 analogues, mechano growth factor and its variants, and thymosin-beta-4 with its derivatives including TB-500. Neither the substance, nor its parent protein, nor adamantane compounds appear anywhere in the annex, and the closing sentence extends the list only to salts, esters, ethers, isomers, complexes and derivatives of the substances named, without any open similarity clause. Controls found in the same text: ipamorelin, TB-500, AICAR, somatropin. Criminal law and sporting law therefore diverge here: not a listed doping agent, yet banned in sport at all times through the catch-all category of the international list.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No authorisation and no product record. This is the weakest row on the page and is labelled as such: no primary document from the regulator was obtained, because the product database renders its results only after running scripts and was not evaluated on 2026-09-16. The negative finding rests on the absence of any product in every other register checked, on the absence of an international non-proprietary name and of an ATC code, and on the fact that no clinical trial with the substance was ever registered anywhere. An unauthorised medicine falls under the Human Medicines Regulations 2012, and supply to consumers is not permitted without an authorisation.","source":"https://products.mhra.gov.uk/search/?search=P021"},{"market":"AU","status":"not_approved","note":"Not in the register of therapeutic goods and not named in the Poisons Standard, so not expressly a prescription-only substance either. The local full text of the June 2026 instrument was searched on 2026-09-16 for the substance name, for both spellings, for adamantane, for leucinamide and for the registry number, with no match; controls found in the same text were ipamorelin, thymosin, semaglutide and growth factor. The standard lists whole classes of growth factors by name in schedule 4 and appendix D, and contains neither the parent protein nor any peptide derived from it, and no open catch-all for peptides. The absence of a listing is not permission: an injectable unlisted substance with a therapeutic purpose may not be imported, advertised or supplied without clearance. A direct full-text query of the register failed with a server error on that date.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not authorised as a medicine and absent from the drug product database. The active-ingredient endpoint returned an empty array for the substance on 2026-09-16, while the control query for an approved medicine returned 49 records on the same endpoint, so the negative finding is verified. Import and supply would require either an authorisation or a clinical trial application.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=P021"},{"market":"CH","status":"not_approved","note":"No authorisation; no primary regulator document naming the substance was obtained, so this row rests on a joint enforcement notice rather than on a register query. In the joint action on peptides of 30 June 2026 by the customs authority, the medicines agency and the sport integrity body, 46 consignments of questionable peptide preparations were checked and 23 held back, 21 of them classed as doping substances and 2 as medicines, with roughly 80 per cent arriving from Poland. No individual peptide is named. The notice states that declarations such as research chemical, not for human use or food supplement change nothing where the products are marketed for use in people.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/56599151"],"lastVerified":"2026-09-16","version":"1.0","published":true,"locale":"en","title":"P021 (P21): what the studies show, status and safety","summary":"P021 is a laboratory molecule built from four amino acids of a nerve growth protein, with a rigid carbon cage attached. No person has ever received it in a registered study, in any phase. Almost every positive finding comes from one group with a commercial interest in the substance, and the single outside test in living animals found nothing. The name also collides with a well-known human protein that is entirely unrelated.","updated":"2026-09-16","url":"https://mypep.app/peptides/p21"}